VarmX Revenue and Competitors
Estimated Revenue & Valuation
- VarmX's estimated annual revenue is currently $4.3M per year.
- VarmX's estimated revenue per employee is $155,000
Employee Data
- VarmX has 28 Employees.
- VarmX grew their employee count by 8% last year.
VarmX's People
| Name | Title | Email/Phone |
|---|
VarmX Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is VarmX?
VarmX (www.varmx.com) is a young Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The VarmX program has gained significant interest in the investment community and a very successful Series B financing round of €32 mill. was closed in 2020.
keywords:N/A
N/A
Total Funding
28
Number of Employees
$4.3M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Leiden
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 30 | -9% | N/A |
#2 | $6.6M | 33 | -8% | N/A |
#3 | $6M | 39 | 3% | N/A |
#4 | $9.2M | 46 | 2% | N/A |
#5 | $13.4M | 55 | 10% | N/A |